Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ASTRAMORPH PF vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Moderate to severe acute pain,Moderate to severe chronic pain,Preoperative sedation,Anesthesia adjunct
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life: 2-4 hours; prolonged in renal impairment (up to 12 hours in anuria) and elderly
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily hepatic via glucuronidation (UGT2B7 and UGT1A3) and minor CYP3A4-mediated N-demethylation to normorphine.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: 70-80% unchanged; Biliary/Fecal: 10-20% as metabolites
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
35% bound; primarily to albumin
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
3-5 L/kg; indicates extensive tissue distribution
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 50-60% (first-pass metabolism); Intramuscular: 80-90%
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
For e GFR 30-50 m L/min: Reduce dose by 25-50% and extend dosing interval to every 12 hours. For e GFR <30 m L/min: Avoid use or reduce dose by 75% and extend interval to every 12-24 hours; monitor for neuroexcitation.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% every 8-12 hours. Child-Pugh C: Avoid use.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Intravenous: 0.1-0.15 mg/kg/dose (max 10 mg) over 2-5 minutes every 8-12 hours as needed. Oral: 0.15-0.3 mg/kg/dose (max 15 mg) every 6-8 hours as needed.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initial dose should be reduced to 50% of adult dose (oral: 5-10 mg every 6-8 hours; IV: 4-5 mg over 2-5 minutes). Titrate slowly; maximum daily dose 60 mg. Avoid extended-release formulations.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental exposure; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Respiratory depression, hypotension, seizures, serotonin syndrome, adrenal insufficiency, severe hypotension, biliary tract spasm, and risks in elderly, cachectic, or debilitated patients.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hypersensitivity to morphine or any component, significant respiratory depression, acute or severe bronchial asthma, GI obstruction, known or suspected paralytic ileus.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No known food interactions. However, alcohol and grapefruit juice may potentiate central nervous system depression and should be avoided.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
ASTRAMORPH PF (morphine sulfate) is Pregnancy Category C. First trimester: No well-controlled studies; potential for neural tube defects if used with other agents. Second/third trimesters: Chronic use may cause fetal opioid dependence and neonatal abstinence syndrome (NAS). Avoid during labor due to risk of neonatal respiratory depression.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Morphine is excreted into breast milk. M/P ratio is approximately 1:1 to 2:1. Limited data suggest low risk at maternal doses ≤30 mg/day; monitor infant for sedation and respiratory depression. Avoid in mothers with high-dose or prolonged use.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific dose adjustment recommended; however, increased clearance in pregnancy may require higher doses for pain control. Use lowest effective dose for shortest duration. Avoid in third trimester near term due to NAS risk.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Astramorph PF (preservative-free morphine sulfate) is indicated for epidural or intrathecal administration. Monitor for delayed respiratory depression, particularly with intrathecal use, as it can occur up to 24 hours post-administration. Use with caution in patients with impaired pulmonary function, head injury, or increased intracranial pressure. Naloxone should be immediately available for reversal. Epidural doses typically range from 2-10 mg; intrathecal doses are 0.1-0.5 mg. Do not use if solution is discolored or contains particulate matter.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Report any difficulty breathing, excessive drowsiness, or nausea immediately.,Avoid driving or operating heavy machinery until you know how this medication affects you.,Do not consume alcohol or other central nervous system depressants while using this medication.,This medication is given directly into the spinal fluid or epidural space; do not attempt to adjust the infusion pump yourself.,If you experience itching, rash, or swelling, contact your healthcare provider.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ASTRAMORPH PF vs ABSTRAL, answered by our medical review team.
ASTRAMORPH PF is a Opioid Analgesic that works by Mu-opioid receptor agonist; produces analgesia, sedation, and euphoria by mimicking endogenous endorphins.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ASTRAMORPH PF and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ASTRAMORPH PF is: Intravenous: 8-10 mg over 2-5 minutes; may be repeated every 8-12 hours as needed. Oral (immediate release): 10-20 mg every 4-6 hours as needed. Oral (extended release): 10-40 mg every 12 hours.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ASTRAMORPH PF and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ASTRAMORPH PF is classified as Category C. ASTRAMORPH PF (morphine sulfate) is Pregnancy Category C. First trimester: No well-controlled studies; potential for neural tube defects if used with other agents. Second/third tri. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.